Fig 6. PI3Ki/MEKi synergism in vitro is influenced by PIK3CAmut and mutant RAS.
Buparlisib and selumetinib inhibited growth and were synergistic in control and PIK3CAmut NHA (A) and NHARAS (B). BLISS showed that synergy was most pronounced with high nanomolar buparlisib and low micromolar/high nanomolar selumetinib in NHA lines. In contrast, synergistic concentrations in NHARAS lines were generally most pronounced at both low micromolar buparlisib and selumetinib.